MSD secures full approval for Keytruda’s use in MSI-high solid tumours
Pharmaceutical Technology
MARCH 30, 2023
On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda.
52 
Let's personalize your content